|Bid||0.00 x 29200|
|Ask||0.00 x 34100|
|Day's Range||2.76 - 2.92|
|52 Week Range||1.86 - 4.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2017 - May 12, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.88|
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
When a biotech company prices a common stock offering, diluting existing shareholders, the stock typically falls. Around $11.1 million of its net income is due to a non-cash gain related to the fall in the fair value of the 2016 private placement warrant liability.
A live webcast of Mr. Bailey’s presentation at the Rodman & Renshaw conference can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.
NEW YORK, NY / ACCESSWIRE / August 27, 2018 / U.S. equities closed up on Friday following Federal Reserve Chairman Jerome Powell's speech, which confirmed the Federal Reserve will gradually normalize monetary ...
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Teradata ...
AVEO Pharmaceuticals, Inc. (AVEO) today announced that it has priced an underwritten public offering of 2,500,000 shares of common stock at a price to the public of $2.26 per share, the closing price as of yesterday, August 16, 2018, which would result in aggregate gross proceeds of approximately $5.7 million before underwriting discounts. All of the shares in the offering are to be sold by AVEO. AVEO has also granted the underwriter a 30-day option to purchase up to an additional 375,000 shares of common stock on the same terms and conditions.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 16) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Eli Lilly And ...
NEW YORK, NY / ACCESSWIRE / August 17, 2018 / U.S. markets bounced back on Thursday after Walmart and Cisco reported upbeat quarterly earnings. The Dow Jones Industrial Average jumped 1.58 percent to close ...
AVEO Pharmaceuticals, Inc. (AVEO) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The net proceeds of the offering are expected to be used for working capital and general corporate purposes, including development and pre-commercial expenses incurred in connection with the ongoing Phase 3 clinical trial of tivozanib in the third-line treatment of patients with advanced renal cell carcinoma (“aRCC”) as well as the ongoing Phase 1b/2 clinical trial of tivozanib in combination with OPDIVO® (nivolumab).
AVEO Oncology (AVEO) today announced that the China National Drug Administration (CNDA) has accepted CANbridge Life Sciences’ Investigational New Drug (IND) Application for a Phase Ib/III clinical trial of CAN017 (AV-203), AVEO’s clinical-stage ErbB3 (HER3) inhibitory antibody candidate, in esophageal squamous cell cancer (ESCC). Under the terms of a March 2016 agreement, the acceptance of this IND triggers a $2 million milestone payment to AVEO from CANbridge Life Sciences. CANbridge licensed worldwide rights, excluding the United States, Canada, and Mexico, to AV-203 from AVEO and AVEO is eligible to receive up to $40 million in potential additional development and regulatory milestone payments and up to $90 million in potential commercial milestone payments, assuming the successful achievement of specified development, regulatory and commercialization objectives.
AVEO (AVEO) delivered earnings and revenue surprises of -150.00% and -67.93%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had profit of 6 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The results did not meet Wall Street expectations. ...
AVEO Oncology today reported financial results for the second quarter ended June 30, 2018 and provided a business update.
AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the Canaccord Genuity 38th Annual Growth Conference in Boston on Wednesday, August 8, 2018 at 4:30 p.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.
On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.
LONDON, UK / ACCESSWIRE / July 24, 2018 / If you want a free Stock Review on AVEO sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
AVEO Pharmaceuticals (AVEO) was a big mover last session, as the company saw its shares rise more than 11% on the day amid huge volumes.
AVEO Oncology (AVEO) today issued the following statement regarding its recently revised guidance on the timing of topline data from the TIVO-3 study, its Phase 3 trial of tivozanib as a third-line treatment for advanced renal cell carcinoma. “The Company expects to report topline results from the TIVO-3 study in the fourth quarter of 2018, approximately 6-8 weeks after the trial records 255 progression free survival (PFS) events. The one-time adjustment in the event count is the result of an administrative error that occurred from counting, as PFS events, the deaths of ten patients who had left the study without documented radiographic progression.
Yesterday, Aveo Pharmaceuticals (AVEO) issued an 8-K filing reporting its plan to release top-line data from its Phase 3 trial TIVO-3 in Q4 2018. In the US Phase 3 registrational study, the company is examining the vascular endothelial growth factor receptor (or VEGFR) 123 tyrosine kinase inhibitor (or TKI) Fotivda (tivozanib) for third-line advanced renal cell carcinoma (or RCC).
NEW YORK, NY / ACCESSWIRE / July 18, 2018 / Shares of AVEO Pharmaceuticals were deep in the red on Tuesday after a SEC 8-K revealed that the company’s TIVO-3 data is now delayed until the fourth quarter. Shares of ACADIA Pharmaceuticals were in the green despite any news. AVEO Pharmaceuticals, Inc. shares closed down 24.21% on Tuesday with nearly 9.4 million shares traded.
NEW YORK, June 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Six ...